This bill reauthorizes and expands the Accelerating Access to Critical Therapies for ALS Act through 2031, extending funding for research into treatments for amyotrophic lateral sclerosis. It requires drug manufacturers to share interim clinical trial data with the FDA to better assess the progress of investigational drugs and clarifies that phase 3 clinical trial definitions include combined phase 2/3 trials and planned trials not yet enrolling participants. The legislation also mandates the FDA to publish an updated five-year action plan for ALS and other rare neurodegenerative diseases, including resource needs and coordination strategies with broader disease communities. Additionally, the bill requires the Government Accountability Office to submit a report on the program's implementation four years after enactment.
Billion Dollar Boondoggle Act This bill requires the Office of Management and Budget (OMB) to collect information from federal agencies and report to Congress regarding projects that are behind schedule or have expenditures that have exceeded the original cost estimate. Specifically, the bill requires OMB to issue guidance directing federal agencies to annually submit specified information to OMB regarding certain federally funded projects that (1) are more than five years behind schedule, or (2) have expenditures that are at least $1 billion more than the original cost estimate for the project. Among other information, the agencies must submit to OMB a description of each project; an explanation of any change to the original scope of the project; the original and current expected dates for the completion of the project; the original and current cost estimates adjusted for inflation; an explanation for any delays in completing the project or increases in the cost; and the amount of and rationale for any award, incentive fee, or other type of bonus awarded for the project. The bill also requires OMB to submit an annual report to Congress containing the information submitted by the agencies and post the report on the OMB website. The report must be submitted in unclassified form, but may include a classified annex.
Reversionary Interest Conveyance Act This bill directs the Bureau of Land Management (BLM) to offer to sell the reversionary interest of the United States in approximately 8.43 acres of land in Sacramento, California, as generally depicted on a specified map dated November 7, 2022. Within two years of receiving a request from the owner of the land, the BLM must offer the reversionary interest and convey the reversionary interest to the buyer upon payment. The payment must be in an amount that is at least the fair market value of the reversionary interest. The buyer must also pay all costs related to the applicable conveyance of the reversionary interest, including all surveys, appraisals, and other administrative costs. The bill subjects the conveyance to valid existing rights. The proceeds from the sale must be deposited into Federal Land Disposal Account.
The Main Street Capital Access Act reduces regulatory burdens for smaller banks, particularly those with less than $10 billion in assets. Key provisions include a 3-year phase-in period for new banks to meet capital requirements, lower leverage ratio requirements for rural banks (7.5% for the first 2 years), and a 30-day review process for business plan deviations. The bill also establishes an Office of Independent Examination Review, sets specific timelines for examinations (270 days) and reports (90 days), and creates a "least cost exception" for bank resolutions to prevent excessive concentration of the banking system. These changes aim to promote new bank formation, improve regulatory efficiency, and support community banking while maintaining financial stability.
North Rim Restoration Act This bill allows the National Park Service (NPS) to expedite the approval of contracts to restore forests, structures, and assets within areas of the Grand Canyon National Park impacted by the Dragon Bravo Fire in Arizona. Specifically, the bill authorizes the NPS to use emergency acquisition flexibilities without a presidential emergency or disaster declaration to contract for the following services in such impacted areas: managing or restoring forests, rebuilding structures affected by the fire, improving grounds and structures, conducting recovery efforts, or other specified activities. This authority expires on the date that is the earlier of the following: (1) seven years after the date of this bill's enactment, or (2) the date on which projects and recovery efforts within such area are completed. The NPS may request Congress extend such authority for 12 months if a new wildfire ignites within such area and impacts recovery efforts related to the Dragon Bravo Fire. The bill also authorizes the NPS to enter into noncompetitive procurement contracts for rebuilding, rehabilitating, replacing, or operating assets, such as lodging or utilities, to support the recovery and reopening of the Grand Canyon National Park North Rim. This authority is conditioned upon the NPS making certain determinations regarding the North Rim concessioner and it terminates seven years after this bill's enactment.
HR 5578 expands whistleblower protections for employees and contractors working with the U.S. Department of Defense (DoD) and National Aeronautics and Space Administration (NASA). It broadens the definition of "protected individual" to include state/local governments, tribal organizations, and intelligence community personnel working under federal contracts. Key changes prohibit retaliation for reporting gross mismanagement, waste, safety dangers, or violations of law, ban forced arbitration waivers that would override these rights, and require disciplinary action against officials who request retaliation. This applies specifically to DoD/NASA contractors under Section 4701 and extends similar protections to all federal contractors under Section 4712 of U.S. Code.
This bill reauthorizes funding for the C.W. Bill Young Cell Transplantation Program, setting $31 million for fiscal year 2025 and $33 million annually for fiscal years 2027-2031. It also extends the deadline for the national cord blood inventory program from 2026 to 2031. The legislation directly affects stem cell research programs and cord blood banks by maintaining federal funding levels and prolonging the inventory program’s timeline. These provisions ensure continuity for existing research infrastructure and blood bank operations without introducing new policy changes.
This bill reauthorizes federal programs focused on preventing and responding to tick-borne diseases through 2026-2030, extending existing efforts beyond their previous expiration. It updates the National Strategy for Vector-Borne Diseases to emphasize identifying, reporting, preventing, and responding to these illnesses. The bill modifies two sections of the Public Health Service Act to continue funding for health departments working on vector-borne disease control. It directly affects public health programs and state/local health departments managing tick-borne disease prevention and response.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
HR 183, the Law Enforcement Officer Recreation Pass Act, creates a free, lifetime National Parks and Federal Recreational Lands Pass for qualifying law enforcement officers. It directly affects federal, state, local, and tribal officers authorized to prevent, detect, or investigate criminal law violations or supervise offenders. The bill amends existing law to require the Secretary to provide this pass without charge, making it available for the passholder's lifetime. This is a concrete policy change expanding access to federal recreation areas for eligible officers, with no cost to them. The bill does not cover firefighters or other public safety personnel.
HR 2913, the Ukraine Support Act, provides comprehensive U.S. support for Ukraine in response to Russia's invasion. The bill authorizes security assistance including lend-lease authority for military equipment, establishes a Ukraine Reconstruction Trust Fund for economic recovery, and imposes new sanctions targeting Russian financial institutions, oil companies, and government officials. It also includes provisions to counter Russian disinformation, support Radio Free Europe, and address the kidnapping of Ukrainian children. The legislation directly affects U.S. foreign policy, Ukraine's defense capabilities, and Russia's access to international financial systems. The act aims to strengthen Ukraine's sovereignty while holding Russia accountable for its actions.
